Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

APPROVED_FOR_MARKETING

Conditions studied: Advanced Cholangiocarcinoma

In brief

The objective of the study is to provide access to TAS-120 to patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements.

Key facts

Study ID

NCT04507503

Run by

Taiho Oncology, Inc.

Last updated by the study team

2026-03-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provide written informed consent.
• >18 years of age.
• Histologically confirmed, locally advanced, or metastatic, or recurrent unresectable CCA harboring FGFR2 gene rearrangements based on testing performed by a qualified (CLIA-certified) laboratory.
• Patient has failed standard therapy or standard therapy is not tolerated.
• Has measurable or non-measurable lesion(s).
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
• Adequate organ function.

You may not qualify if…

• History and/or current evidence of non-tumor related alteration of calcium-phosphorus homeostasis.
• History and/or current evidence of clinically significant ectopic mineralization/calcification.
• History and/or current evidence of clinically significant retinal disorder confirmed by retinal examination.
• A serious illness or medical condition(s)
• Pregnant or breast-feeding female

Where it is running

• Banner MD Anderson — Gilbert, Arizona, United States
• University of California, San Francisco (UCSF) — San Francisco, California, United States
• UCLA Division of Hematology-Oncology — Santa Monica, California, United States
• Mount Sinai Center of Florida — Miami Beach, Florida, United States
• Advent Health Orlando — Orlando, Florida, United States
• University of Chicago — Chicago, Illinois, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• University of Kansas Cancer Center — Lee's Summit, Missouri, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Providence Portland Medical Center — Portland, Oregon, United States
• MD Anderson — Houston, Texas, United States
• Utah Cancer Specialists — Salt Lake City, Utah, United States
• Seattle Cancer Care Alliance — Seattle, Washington, United States
• Aurora Cancer care — Grafton, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.